Literature DB >> 30056096

Effects of Allocating Livers for Transplantation Based on Model for End-Stage Liver Disease-Sodium Scores on Patient Outcomes.

Shunji Nagai1, Lucy C Chau2, Randolph E Schilke2, Mohamed Safwan2, Michael Rizzari2, Kelly Collins2, Atsushi Yoshida2, Marwan S Abouljoud2, Dilip Moonka3.   

Abstract

BACKGROUND & AIMS: The Model for End-stage Liver Disease and Sodium (MELD-Na) score was introduced for liver allocation in January 2016. We evaluated the effects of liver allocation, based on MELD-Na score, on waitlist and post-transplantation outcomes.
METHODS: We examined 2 patient groups from the United Network for Organ Sharing registry; the MELD-period group was composed of patients who were registered as transplant candidates from June 18, 2013 through January 10, 2016 (n = 18,850) and the MELD-Na period group was composed of patients who were registered from January 11, 2016 through September 30, 2017 (n = 14,512). We compared waitlist and post-transplantation outcomes and association with serum sodium concentrations between groups.
RESULTS: Mortality within 90 days on the liver waitlist decreased (hazard ratio [HR] 0.738, P < .001) and transplantation probability increased significantly (HR 1.217, P < .001) in the MELD-Na period. Although mild, moderate, and severe hyponatremia (130-134, 125-129, and <125 mmol/L) were independent risk factors for waitlist mortality in the MELD period (HR 1.354, 1.762, and 2.656; P < .001, P < .001, and P < .001, respectively) compared with the reference standard (135-145 mmol/L), these adverse outcomes were decreased in the MELD-Na period (HR 1.092, 1.271 and 1.374; P = .27, P = .018, and P = .037, respectively). The adjusted survival benefit of transplant recipients vs patients placed on the waitlist in the same score categories was definitive for patients with MELD-Na scores of 21-23 in the MELD-Na era (HR 0.336, P < .001) compared with MELD scores of 15-17 in the MELD era (HR 0.365, P < .001).
CONCLUSIONS: Liver allocation based on MELD-Na score successfully improved waitlist outcomes and provided significant benefit to hyponatremic patients. Given the discrepancy in transplantation survival benefit, the current rules for liver allocation might require revision.
Copyright © 2018 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Hyponatremia; Survival Benefit; United Network for Organ Sharing; Waitlist Mortality

Mesh:

Substances:

Year:  2018        PMID: 30056096     DOI: 10.1053/j.gastro.2018.07.025

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  13 in total

1.  MELD 3.0: The Model for End-Stage Liver Disease Updated for the Modern Era.

Authors:  W Ray Kim; Ajitha Mannalithara; Julie K Heimbach; Patrick S Kamath; Sumeet K Asrani; Scott W Biggins; Nicholas L Wood; Sommer E Gentry; Allison J Kwong
Journal:  Gastroenterology       Date:  2021-09-03       Impact factor: 22.682

2.  Extreme hyponatremia as a risk factor for early mortality after liver transplantation in the MELD-sodium era.

Authors:  Tommy Ivanics; Shravan Leonard-Murali; Hassan Mouzaihem; Dilip Moonka; Toshihiro Kitajima; Sirisha Yeddula; Mhd Tayseer Shamaa; Michael Rizzari; Kelly Collins; Atsushi Yoshida; Marwan Abouljoud; Shunji Nagai
Journal:  Transpl Int       Date:  2021-10-07       Impact factor: 3.782

Review 3.  A Comprehensive Review of Outcome Predictors in Low MELD Patients.

Authors:  Nikhilesh R Mazumder; Kofi Atiemo; Matthew Kappus; Giuseppe Cullaro; Matthew E Harinstein; Daniela Ladner; Elizabeth Verna; Jennifer Lai; Josh Levitsky
Journal:  Transplantation       Date:  2020-02       Impact factor: 5.385

Review 4.  Hospice care for end stage liver disease in the United States.

Authors:  Eric S Orman; Amy W Johnson; Marwan Ghabril; Greg A Sachs
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2021-02-24       Impact factor: 4.095

5.  Predictive value of the Chinese group on the study of severe hepatitis B-acute-on-chronic liver failure score in the short-term prognosis of patients with hepatitis B virus-related acute-on-chronic liver failure.

Authors:  Jing-Jing Tong; Wei Zhao; Xiu-Ying Mu; Xiang Xu; Hai-Bin Su; Xiao-Yan Liu; Jing Chen; Xing-Ran Zhai; Yu Wang; Jin-Hua Hu
Journal:  Chin Med J (Engl)       Date:  2019-07-05       Impact factor: 2.628

Review 6.  Assessment of Malnutrition, Sarcopenia and Frailty in Patients with Cirrhosis: Which Tools Should We Use in Clinical Practice?

Authors:  Benjamin Buchard; Yves Boirie; Lucie Cassagnes; Géraldine Lamblin; A Coilly; Armando Abergel
Journal:  Nutrients       Date:  2020-01-09       Impact factor: 5.717

7.  Validation of the Model for End-stage Liver Disease sodium (MELD-Na) score in the Eurotransplant region.

Authors:  Ben F J Goudsmit; Hein Putter; Maarten E Tushuizen; Jan de Boer; Serge Vogelaar; I P J Alwayn; Bart van Hoek; Andries E Braat
Journal:  Am J Transplant       Date:  2020-08-04       Impact factor: 8.086

8.  Impact on Waitlist Outcomes from Changes in the Medical Eligibility of Candidates for Simultaneous Liver-Kidney Transplantation Following Implementation of the 2017 Organ Procurement and Transplantation Network/United Network for Organ Sharing Policy in the United States.

Authors:  Shingo Shimada; Toshihiro Kitajima; Yukiko Suzuki; Yasutaka Kuno; Tayseer Shamaa; Tommy Ivanics; Kelly Collins; Michael Rizzari; Atsushi Yoshida; Marwan Abouljoud; Dilip Moonka; Shunji Nagai
Journal:  Ann Transplant       Date:  2022-02-18       Impact factor: 1.530

9.  Extra-hepatic comorbidity burden significantly increases 90-day mortality in patients with cirrhosis and high model for endstage liver disease.

Authors:  Scott Coppel; Karan Mathur; Burcin Ekser; Kavish R Patidar; Eric Orman; Archita P Desai; Eduardo Vilar-Gomez; Chandrashekhar Kubal; Naga Chalasani; Lauren Nephew; Marwan Ghabril
Journal:  BMC Gastroenterol       Date:  2020-09-16       Impact factor: 3.067

10.  Refitting the Model for End-Stage Liver Disease for the Eurotransplant Region.

Authors:  Jacques Pirenne; Bart van Hoek; Andries E Braat; Ben F J Goudsmit; Hein Putter; Maarten E Tushuizen; Serge Vogelaar; Ian P J Alwayn
Journal:  Hepatology       Date:  2021-05-09       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.